hydroxychloroquine plus macrolides - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.64 [0.18, 2.24]< 10%1 study (1/-)75.7 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.64 [0.18, 2.24]< 10%1 study (1/-)75.7 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.99 [0.57, 1.72]< 10%1 study (1/-)51.4 %some concernnot evaluable moderateimportant-
clinical improvement 0.81 [0.54, 1.22]> 10%1 study (1/-)15.5 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.01 [0.58, 1.76]> 10%1 study (1/-)51.4 %some concernnot evaluable moderateimportant-
mechanical ventilation 1.77 [0.81, 3.87]< 10%1 study (1/-)7.6 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 1.87 [0.36, 9.75]< 10%1 study (1/-)23.0 %some concernnot evaluable moderateimportant-
acute kidney injury 1.18 [0.44, 3.18]< 10%1 study (1/-)37.2 %some concernnot evaluable moderatenon important-
adverse events 2.22 [1.43, 3.44]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-
arrhythmia 2.24 [0.23, 21.69]< 10%1 study (1/-)24.5 %some concernnot evaluable moderatenon important-
elevated liver enzymes 3.48 [1.40, 8.64]< 10%1 study (1/-)0.4 %some concernnot evaluable moderatenon important-
long QT 9.79 [1.27, 75.50]< 10%1 study (1/-)1.5 %some concernnot evaluable moderatenon important-

AE of interest endpoints 00

Thromboembolic events 0.89 [0.31, 2.55]< 10%1 study (1/-)58.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.